Skip to content
Peptidepedia

Tirzepatide Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timeline

  • Weeks 1–4: 2–4% weight loss; appetite suppression typically begins within the first week
  • Weeks 4–12: 5–10% body weight reduction; glycemic improvements emerge within 4–8 weeks
  • Weeks 12–24: 15–18% body weight reduction at higher doses
  • Weeks 24–72: Up to 22.5% average weight loss at 15 mg; plateau typically reached by 52–72 weeks

Individual responses vary based on dose, adherence, dietary habits, activity levels, and baseline metabolic health. Weight loss trajectories are generally progressive over the first year before reaching a plateau.

Frequently Asked Questions

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide targets only GLP-1 receptors. Head-to-head trials (SURPASS-2) show tirzepatide produces greater weight loss and HbA1c reduction at all doses compared to semaglutide 1 mg weekly.

Most people notice appetite changes within the first week, with measurable weight loss within 2-4 weeks. Significant results of 10%+ body weight reduction require 12-24 weeks of consistent treatment. Maximum weight loss typically occurs by 52-72 weeks.

Weight regain is common after discontinuation. The SURMOUNT-4 trial showed participants regained approximately two-thirds of lost weight within one year of stopping. Long-term or indefinite use may be necessary to maintain results. For a comparison with the next-generation triple agonist, see our [tirzepatide vs retatrutide guide](/guides/tirzepatide-vs-retatrutide).

If fewer than 4 days (96 hours) have passed since the missed dose, administer it immediately. If more than 4 days have passed, skip the missed dose and resume your regular weekly schedule. Do not double dose.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
  3. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
  4. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
  5. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness. Cardiovasc Diabetol. 2022;21(1):66.
  6. Samms RJ, et al. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.
  7. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 2023.
  8. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2022.
  9. World Anti-Doping Agency. The Prohibited List 2024.
  10. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
←Read the full Tirzepatide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”